Researchers develop blood test for stress

Published Date: 08 Mar 2023

Researchers at Indiana University School of Medicine have developed a blood test for stress. This test assesses a person's risk of stress,...

Read Full News

Latest News

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

4 Psychiatry Headlines You Missed in November 2025

4 Psychiatry Headlines You Missed in November 2025

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Todays Updates

NeurologyLive® Year in Review 2025: Notable Trials Beginning This Year NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.

NeuroVoices: Joseph Sullivan, MD, on ETX101 Gene Regulation Therapy and Early POLARIS Findings in Dravet Syndrome Marco Meglio

The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.

NeurologyLive® Year in Review 2025: Top Interviews in Multiple Sclerosis Care NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.

Hidradenitis Suppurativa in 2025: Year in Review

Hidradenitis Suppurativa in 2025: Year in Review

Todays Updates

NeurologyLive® Year in Review 2025: Notable Trials Beginning This Year NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.

NeuroVoices: Joseph Sullivan, MD, on ETX101 Gene Regulation Therapy and Early POLARIS Findings in Dravet Syndrome Marco Meglio

The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.

NeurologyLive® Year in Review 2025: Top Interviews in Multiple Sclerosis Care NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.

Hidradenitis Suppurativa in 2025: Year in Review

Hidradenitis Suppurativa in 2025: Year in Review

Latest News

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

4 Psychiatry Headlines You Missed in November 2025

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

News All Time

5 Psychiatry Headlines You Missed in September 2025 Chelsie Derman

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

Soft Drinks Linked to Depression Through Gut Microbiota Alterations Chelsie Derman

New research links soft drink consumption to depression, revealing gut microbiota changes as a potential mediator, particularly in women.

Early Heart Rate Slowing Predicts Magnetic Brain Stimulation Response in MDD Chelsie Derman

Study finds heart rate deceleration within 45 seconds of iTBS may serve as a biomarker for improved depression outcomes, regardless of stimulation site.

Digital Therapeutic Reduces Negative Symptoms of Schizophrenia in Phase 3 Trial Chelsie Derman

A new digital therapeutic, CT-155, shows promise in reducing negative symptoms of schizophrenia.

FDA Approves Risperidone Extended-Release Injectable for Bipolar I Disorder Chelsie Derman

FDA approves UZEDY, a long-acting risperidone injection, for adults with bipolar I disorder.

Esmethadone Shows Promise as Adjunctive Treatment for Antidepressant Tolerance Chelsie Derman

Post-hoc analysis of a phase 3 trial reveals significant improvements in patients with MDD experiencing tachyphylaxis.

Magnetic Seizure Therapy Rivals ECT, Protects Cognition in Adolescent MDD Chelsie Derman

A study found magnetic seizure therapy matched ECT’s antidepressant efficacy while offering better cognitive preservation and fewer adverse events.

Antidepressants Differ Significantly in Cardiometabolic Side Effects Chelsie Derman

A large analysis reveals clinically relevant differences in weight, blood pressure, and heart rate across 30 antidepressants.

Repetitive TMS Boosts Quality of Life in Younger, Older Adults with Depression Chelsie Derman

Study finds repetitive transcranial magnetic stimulation brings clinically meaningful improvements in quality of life for adults with MDD through 12 weeks.

Comorbid Anxiety Lowers Accelerated Theta Burst Response in Depression Chelsie Derman

A study finds older adults with depression and comorbid anxiety show less improvement after accelerated theta burst stimulation.

Rethinking Addiction Recovery: From Symptoms to Systems

Rethinking Addiction Recovery: From Symptoms to Systems

Non-Invasive Vagus Nerve Stimulation Boosts Food Liking in Depression Chelsie Derman

Right transcutaneous auricular VNS (taVNS) acutely increases food liking in patients with MDD, especially those with high anhedonia, a study found.

Women Face Higher Risk of Advanced Fibrosis Due to Binge Drinking Than Men

Women Face Higher Risk of Advanced Fibrosis Due to Binge Drinking Than Men

Stigma Around Alcohol-Related Liver Disease Poses Major Barrier to Care

Stigma Around Alcohol-Related Liver Disease Poses Major Barrier to Care

6 Psychiatry Headlines You Missed in October 2025

6 Psychiatry Headlines You Missed in October 2025

Tracing schizophrenia's origins: Study maps chromatin accessibility in postmortem brain tissue

Schizophrenia is a severe neuropsychiatric disorder characterized by hallucinations, false beliefs about oneself or the world (i.e., delusions), and other disruptions in thought, emotion and perception. Recent genetic studies ...

Recommended News For You

Patient Endured 9 Years of Chemotherapy for Cancer He Never Had

Don't Call It Cancer; Clues to 'Exceptional' Responses; More Predictions for 2025

Medical Journal March 29, 2023

recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.

Watch for Psoriasis After Cancer Immunotherapy, Study Says

DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance

Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.

Recommended Articles For You

Innovative Marketing Strategies for Oncology Drugs: A Clinician’s Take on Digital and B2B Trends 

Exploring the Causes and Treatments of Thrombocytopenia: A Comprehensive Guide 

Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer 

Intrapancreatic Fat, Pancreatitis, and Cancer: Role of Cancer-Associated Fibroblasts 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Higher levels of HIF2α found to slow down aggressive childhood cancer

2.

Increased anti-tumor response and reduced side effects from immune checkpoint inhibitors.

3.

Researchers identify potential new therapeutic targets for treating T-cell lymphoma and natural killer cell tumors.

4.

Taking the "Boob Bus"; Reluctance to Grant Prior Authorization; Alcohol's Carcinogenic Potential?

5.

Significant differences in breast cancer care still exist, but surgeons can change.

1.

Treating Methemoglobinemia: What You Need to Know Now!

2.

Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025

3.

Exploring the Unseen: Carcinoid Syndrome and its Impact on Quality of Life

4.

Uncovering the Mystery of the Sessile Serrated Adenoma

5.

Innovative Marketing Strategies for Oncology Drugs: A Clinician’s Take on Digital and B2B Trends

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

2.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III

3.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I

4.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I

5.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot